Detalhe da pesquisa
1.
Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): two multicentre, double-blind, randomised controlled trials.
Lancet
; 375(9712): 396-407, 2010 Jan 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-20074791
2.
Activity of elvitegravir, a once-daily integrase inhibitor, against resistant HIV Type 1: results of a phase 2, randomized, controlled, dose-ranging clinical trial.
J Infect Dis
; 201(6): 814-22, 2010 Mar 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-20146631
3.
Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial.
Lancet
; 374(9692): 796-806, 2009 Sep 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-19647866
4.
Efficacy and safety of etravirine (TMC125) in patients with highly resistant HIV-1: primary 24-week analysis.
AIDS
; 21(6): F1-10, 2007 Mar 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-17413684
5.
Endoscopic Third Ventriculostomy in Patients with Neurofibromatosis Type 1: A Multicenter International Experience.
World Neurosurg
; 107: 623-629, 2017 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-28842232
6.
Pilot study of once-daily simplification therapy with abacavir/lamivudine/zidovudine and efavirenz for treatment of HIV-1 infection.
HIV Clin Trials
; 7(5): 229-36, 2006.
Artigo
em Inglês
| MEDLINE | ID: mdl-17162316
7.
A new era in HCV treatment.
Posit Aware
; 23(3): 42-3, 2011.
Artigo
em Inglês
| MEDLINE | ID: mdl-21776910
8.
Abacavir, efavirenz, didanosine, with or without hydroxyurea, in HIV-infected adults failing initial nucleoside/protease inhibitor-containing regimens.
BMC Infect Dis
; 5: 23, 2005 Apr 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-15819974
9.
The biography of an HIV doctor. A 20-year retrospective.
Posit Aware
; 20(1): 43-5, 2009.
Artigo
em Inglês
| MEDLINE | ID: mdl-19205097
10.
We mourn our great loss. Paying homage to Martin Delaney. 1945-2009.
Posit Aware
; 20(2): 16-7, 2009.
Artigo
em Inglês
| MEDLINE | ID: mdl-19280740
11.
Comparing two integrase inhibitors. The first head-to-head study comparing raltegravir and elvitegravir.
Posit Aware
; 19(5): 49-51, 2008.
Artigo
em Inglês
| MEDLINE | ID: mdl-18831079
12.
Sexual encounters with undetectable HIV-positive men. A controversy about HIV transmission.
Posit Aware
; 19(6): 59-61, 2008.
Artigo
em Inglês
| MEDLINE | ID: mdl-19062412
13.
Syphilis complications after starting treatment for HIV. One patient's story.
Posit Aware
; 18(4): 36-7, 2007.
Artigo
em Inglês
| MEDLINE | ID: mdl-17682282
14.
The importance of being earnest. Specific advantages and new treatment options for the un-undetectable.
Posit Aware
; 18(2): 37, 2007.
Artigo
em Inglês
| MEDLINE | ID: mdl-17390490
15.
A new approach: immune-based treatments against HIV.
Posit Aware
; 18(3): 43-4, 2007.
Artigo
em Inglês
| MEDLINE | ID: mdl-17526118
16.
The dawn of a new treatment. A look at experimental HIV integrase inhibitors.
Posit Aware
; 17(3): 44-5, 2006.
Artigo
em Inglês
| MEDLINE | ID: mdl-16791964
17.
New protease inhibitor TMC-114. Preliminary 24-week late breaker results of the phase II trial.
Posit Aware
; 16(2): 27, 41, 2005.
Artigo
em Inglês
| MEDLINE | ID: mdl-15828108
18.
Minocycline shown to have protection for the brain against HIV. Results of a preclinical study recently published in JAMA.
Posit Aware
; 16(4): 49-50, 2005.
Artigo
em Inglês
| MEDLINE | ID: mdl-16110546
19.
A new era in HIV treatment: the entry inhibitors.
Posit Aware
; 16(1): 51-3, 2005.
Artigo
em Inglês
| MEDLINE | ID: mdl-17390505
20.
Raltegravir versus Efavirenz regimens in treatment-naive HIV-1-infected patients: 96-week efficacy, durability, subgroup, safety, and metabolic analyses.
J Acquir Immune Defic Syndr
; 55(1): 39-48, 2010 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-20404738